Nasus Pharma Ltd NSRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
-
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
-
Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
Nasus Pharma Announces Transition of Chief Financial Officer
-
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 11.71M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.nasuspharma.com
Valuation
|
Metric
|
NSRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.11 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NSRX
|
|---|---|
Quick Ratio | 8.42 |
Current Ratio | 8.77 |
Interest Coverage | — |
Quick Ratio
NSRX
Profitability
|
Metric
|
NSRX
|
|---|---|
Return on Assets (Normalized) | −151.28% |
Return on Equity (Normalized) | −289.62% |
Return on Invested Capital (Normalized) | −228.76% |
Return on Assets
NSRX
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#mv$H%l | LOCK|czy | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|J^Y?C? | LOCK|&& | $665B | |||
| AbbVie Inc
ABBV
| LOCK|lX%^YC | LOCK|G? | $521B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|bm#!zcpH | LOCK|?q | $386B | |||
| Merck & Co Inc
MRK
| LOCK|P!?$^cF | LOCK|>Hf | $371B | |||
| Novartis AG ADR
NVS
| LOCK|SrW%sY&q | LOCK|N?# | $309B | |||
| AstraZeneca PLC
AZN
| LOCK|dXb%w%jT | LOCK|PL? | $286B | |||
| Amgen Inc
AMGN
| LOCK|ws^#^BT | LOCK|?! | $259B | |||
| Gilead Sciences Inc
GILD
| LOCK|K^%$tFG | LOCK|nvn | $216B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Fxqx$f | LOCK|v@< | $189B |
United States